Arkadios Wealth Advisors Grows Position in Veeva Systems Inc. $VEEV

Arkadios Wealth Advisors raised its holdings in Veeva Systems Inc. (NYSE:VEEV) by 9.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,632 shares of the technology company’s stock after acquiring an additional 327 shares during the quarter. Arkadios Wealth Advisors’ holdings in Veeva Systems were worth $1,046,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in VEEV. Vanguard Group Inc. lifted its stake in shares of Veeva Systems by 2.2% in the first quarter. Vanguard Group Inc. now owns 14,760,566 shares of the technology company’s stock valued at $3,418,990,000 after purchasing an additional 315,421 shares during the period. Alliancebernstein L.P. increased its holdings in Veeva Systems by 10.7% in the first quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock valued at $1,273,884,000 after buying an additional 532,269 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Veeva Systems by 0.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 5,203,867 shares of the technology company’s stock valued at $1,205,372,000 after acquiring an additional 34,169 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Veeva Systems by 20.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after acquiring an additional 689,700 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Veeva Systems by 7.5% during the 1st quarter. JPMorgan Chase & Co. now owns 3,230,758 shares of the technology company’s stock worth $748,341,000 after acquiring an additional 225,125 shares in the last quarter. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Veeva Systems

In related news, insider Eleni Nitsa Zuppas sold 6,000 shares of the company’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total value of $1,839,720.00. Following the completion of the transaction, the insider directly owned 25,325 shares in the company, valued at approximately $7,765,151.50. This represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Thomas D. Schwenger sold 3,350 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total value of $1,005,134.00. Following the transaction, the insider owned 23,773 shares in the company, valued at $7,132,850.92. This trade represents a 12.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 24,665 shares of company stock worth $7,438,000. Insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

VEEV has been the subject of several research analyst reports. Wall Street Zen raised Veeva Systems from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Oppenheimer restated an “outperform” rating and issued a $325.00 price target on shares of Veeva Systems in a research report on Thursday, August 28th. JPMorgan Chase & Co. raised Veeva Systems from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $290.00 to $330.00 in a research note on Monday, September 8th. Truist Financial lifted their price target on Veeva Systems from $268.00 to $275.00 and gave the stock a “hold” rating in a research note on Thursday, August 28th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $340.00 price target (up previously from $310.00) on shares of Veeva Systems in a research note on Thursday, August 28th. Seventeen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $307.58.

Veeva Systems Trading Up 2.2%

Shares of VEEV stock opened at $291.20 on Friday. The company has a market capitalization of $47.73 billion, a price-to-earnings ratio of 59.80, a PEG ratio of 2.22 and a beta of 0.98. The firm has a 50-day moving average price of $285.22 and a 200 day moving average price of $272.54. Veeva Systems Inc. has a twelve month low of $201.54 and a twelve month high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). The firm had revenue of $789.08 million for the quarter, compared to analysts’ expectations of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 earnings per share. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. As a group, research analysts predict that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.